229 related articles for article (PubMed ID: 31911552)
1. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
[TBL] [Abstract][Full Text] [Related]
2. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
3. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease.
D'Souza S; del Prete D; Jin S; Sun Q; Huston AJ; Kostov FE; Sammut B; Hong CS; Anderson JL; Patrene KD; Yu S; Velu CS; Xiao G; Grimes HL; Roodman GD; Galson DL
Blood; 2011 Dec; 118(26):6871-80. PubMed ID: 22042697
[TBL] [Abstract][Full Text] [Related]
4. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
5. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.
Gowda PS; Wildman BJ; Trotter TN; Xu X; Hao X; Hassan MQ; Yang Y
Mol Cancer Res; 2018 Jul; 16(7):1138-1148. PubMed ID: 29592898
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
[TBL] [Abstract][Full Text] [Related]
7. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
8. Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC.
Ozerova M; Nefedova Y
Leuk Lymphoma; 2019 Jun; 60(6):1557-1562. PubMed ID: 30601091
[TBL] [Abstract][Full Text] [Related]
9. Myeloma cell-derived Runx2 promotes myeloma progression in bone.
Trotter TN; Li M; Pan Q; Peker D; Rowan PD; Li J; Zhan F; Suva LJ; Javed A; Yang Y
Blood; 2015 Jun; 125(23):3598-608. PubMed ID: 25862559
[TBL] [Abstract][Full Text] [Related]
10. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.
Ramachandran IR; Martner A; Pisklakova A; Condamine T; Chase T; Vogl T; Roth J; Gabrilovich D; Nefedova Y
J Immunol; 2013 Apr; 190(7):3815-23. PubMed ID: 23460744
[TBL] [Abstract][Full Text] [Related]
11. Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth.
Kreps LM; Addison CL
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805598
[TBL] [Abstract][Full Text] [Related]
12. Bone Marrow Neutrophils of Multiple Myeloma Patients Exhibit Myeloid-Derived Suppressor Cell Activity.
Petersson J; Askman S; Pettersson Å; Wichert S; Hellmark T; Johansson ÅCM; Hansson M
J Immunol Res; 2021; 2021():6344344. PubMed ID: 34414242
[TBL] [Abstract][Full Text] [Related]
13. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
Akech J; Wixted JJ; Bedard K; van der Deen M; Hussain S; Guise TA; van Wijnen AJ; Stein JL; Languino LR; Altieri DC; Pratap J; Keller E; Stein GS; Lian JB
Oncogene; 2010 Feb; 29(6):811-21. PubMed ID: 19915614
[TBL] [Abstract][Full Text] [Related]
14. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.
Giuliani N; Colla S; Morandi F; Lazzaretti M; Sala R; Bonomini S; Grano M; Colucci S; Svaldi M; Rizzoli V
Blood; 2005 Oct; 106(7):2472-83. PubMed ID: 15933061
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
16. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
Metzger P; Kirchleitner SV; Boehmer DFR; Hörth C; Eisele A; Ormanns S; Gunzer M; Lech M; Lauber K; Endres S; Duewell P; Schnurr M; König LM
Cancer Immunol Immunother; 2020 Oct; 69(10):2101-2112. PubMed ID: 32448983
[TBL] [Abstract][Full Text] [Related]
17. Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.
Zhuang J; Zhang J; Lwin ST; Edwards JR; Edwards CM; Mundy GR; Yang X
PLoS One; 2012; 7(11):e48871. PubMed ID: 23173040
[TBL] [Abstract][Full Text] [Related]
18. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
Edwards CM; Edwards JR; Lwin ST; Esparza J; Oyajobi BO; McCluskey B; Munoz S; Grubbs B; Mundy GR
Blood; 2008 Mar; 111(5):2833-42. PubMed ID: 18094333
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
Schafer CC; Wang Y; Hough KP; Sawant A; Grant SC; Thannickal VJ; Zmijewski J; Ponnazhagan S; Deshane JS
Oncotarget; 2016 Nov; 7(46):75407-75424. PubMed ID: 27705910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
